ATLASATLAS fair value
₩90,843
Below fair value · 17% discount
Range: ₩67,383–₩119,343Fair valuePrice
Sk Biopharmaceuticals (326030.KO)
Sk Biopharmaceuticals stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · Korea Exchange (KOSPI) · South Korea
₩75,800▼ -1.43%
Prices as of Oct 26, 2026 · KRW
Chance of rising in 1 month
50%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Sk Biopharmaceuticals in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Sk Biopharmaceuticals
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS estimates Sk Biopharmaceuticals's fair value at about ₩90,843 per share (reasonable range: ₩67,383 to ₩119,343). At ₩75,800, the stock trades 17% below it.
It is calculated with a blend of a discounted cash-flow model and peer valuation multiples. Confidence in the estimate is medium. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Sk Biopharmaceuticals a 50% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₩70,640 and ₩81,181; in 9 out of 10, between ₩62,445 and ₩91,835. Estimated annual volatility is 39%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₩5.4T
- Market cap (USD)
- $4.1B
- P/E ratio
- 14.6
- 52-week high
- ₩144,100
- 52-week low
- ₩67,800
- Revenue (12 months)
- ₩861B
- Gross margin
- 94.0%
- Operating margin
- 39.2%
- Net margin
- 46.6%
- Beta
- 0.71
What this means
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Sk Biopharmaceuticals sits below fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks 326030.KO has traded between ₩67,800 and ₩144,100. Today it is 47.4% below that high and 12% above its low.
On the business: net margin is 46.6%; it trades at 14.6 times earnings.
Its beta is 0.71: it tends to move less than the market.
About the company
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication.
Want to see everything about Sk Biopharmaceuticals?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What is Sk Biopharmaceuticals (326030.KO) fair value?
About ₩90,843 per share according to ATLAS (reasonable range: ₩67,383 to ₩119,343). With the stock at ₩75,800, it is 17% below it.
What is the chance 326030.KO goes up next month?
50%: close to a coin flip. In half of the simulated outcomes, 326030.KO ends the month between ₩70,640 and ₩81,181.
How big is Sk Biopharmaceuticals and what is its P/E ratio?
Sk Biopharmaceuticals's market capitalization is ₩5.4T. Its price-to-earnings (P/E) ratio is 14.6: you pay ₩14.6 for each ₩1.00 of yearly earnings.
How volatile is 326030.KO?
ATLAS estimates annual volatility at 39%. In a typical month, half of the outcomes end between ₩70,640 and ₩81,181.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer